Form 4: Theravance Biopharma Executive Aine Miller Acquires and Disposes of Shares

Aine Miller, SVP at Theravance Biopharma, reports acquisition of 10,430 shares via RSU vesting and disposition of 9,701 shares to cover tax obligations.

Summary

• Aine Miller, a Senior Vice President at Theravance Biopharma, filed a Form 4 detailing changes in beneficial ownership.
• On May 19, 2025, Miller acquired 10,430 ordinary shares through the vesting of performance-based restricted stock units (RSUs).
• These RSUs vested because performance conditions were met, and the shares are now eligible to vest based on continued service.
• On May 20, 2025, Miller disposed of 9,701 ordinary shares at a price of $9.45 per share.
• These shares were withheld by the company to satisfy tax obligations related to the vesting of previously granted RSUs.
• Following these transactions, Miller beneficially owns 214,990 ordinary shares.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing. The vesting of RSUs is generally a positive sign, but the sale of shares to cover taxes is neutral.

Positives

• The vesting of performance-based RSUs indicates that performance conditions were met, which could be viewed positively.

Industry Context

Form 4 filings are standard disclosures required by the SEC for insiders of publicly traded companies, providing transparency into their transactions in the company's stock.

Related Party Transactions

• The share withholding transaction to cover tax obligations is a transaction with the issuer.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect insider activity related to compensation.

Key Dates

Keywords

Form 4, Theravance Biopharma, Beneficial Ownership, RSU, Aine Miller, TBPH, Shares, Vesting, Tax Obligations